Immune Exhaustion and Immune Senescence: Two Distinct Pathways for HBV Vaccine Failure During HCV and/or HIV Infection
- First Online:
- Cite this article as:
- Yao, Z.Q. & Moorman, J.P. Arch. Immunol. Ther. Exp. (2013) 61: 193. doi:10.1007/s00005-013-0219-0
- 892 Views
Given the shared risk factors for transmission, co-infection of hepatitis B virus (HBV) with hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) is quite common, and may lead to increases in morbidity and mortality. As such, HBV vaccine is recommended as the primary means to prevent HBV super-infection in HCV- and/or HIV-infected individuals. However, vaccine response (sero-conversion with a hepatitis B surface antibody titer >10 IU/L) in this setting is often blunted, with poor response rates to standard HBV vaccinations in virally infected individuals when compared with the healthy subjects. This phenomenon also occurs to other vaccines in adults, such as pneumococcal and influenza vaccines, in other immunocompromised hosts who are really at risk for opportunistic infections, such as individuals with hemodialysis, transplant, and malignancy. In this review, we summarize the underlying mechanisms involving vaccine failure in these conditions, focusing on immune exhaustion and immune senescence—two distinct signaling pathways regulating cell function and fate. We raise the possibility that blocking these negative signaling pathways might improve success rates of immunizations in the setting of chronic viral infection.
KeywordsImmune exhaustionImmune senescenceHCVHIVHBV vaccine response
Hepatitis B virus
Hepatitis C virus
Human immunodeficiency virus
Hepatitis B surface antigen
Hepatitis B e antigen
Hepatitis A virus
Human leukocyte antigen
Suppressor of cytokine signaling-1
T cell immunoglobulin domain protein-3
Regulatory T cells
Killer cell lectin like receptor G-1
- ATR and ATM
Ataxia telangiectasia Rad3-related and ataxia telangiectasia mutated kinases
Super-infection with bacterial, fungal, or viral pathogens in individuals with chronic viral infections, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) is common. Other immunocompromised conditions, such as transplantation, hemodialysis, and malignancy, are also common clinical scenarios in which super-infections occur. As such, recommendations for immunization with available vaccines in adults have been generated to prevent the morbidity and mortality associated with super-infection in these hosts. Unfortunately, these patients often do not respond well to vaccinations. This review focuses on this problem, discussing the potential mechanisms underlying poor vaccine responses and possible approaches to increase the vaccine success rates in immunocompromised hosts.
Co-Infection of HBV with HIV or HCV Increases Liver-Related Morbidity and Mortality
In the Multi-center AIDS Cohort Study, HIV/HBV co-infected men were almost 19 times more likely to die of liver disease than those infected with HBV alone, and eight times more likely to die of liver disease than those infected with HIV-1 alone (Thio et al. 2002). In an observational study of more than 23,000 HIV-infected patients done in Switzerland, active HBV infection measured as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV-DNA-positive was an independent predictor of liver-related death with an adjusted relative risk of 3.73 (Weber et al. 2006). In the general adult population in western countries such as Australia, US, and Italy, the risk of developing chronic hepatitis after contracting HBV is 5–10 %; this number, however, can be doubled or even tripled in HBV/HIV co-infected patients, not to mention in HBV/HIV/HCV-infected individuals (Bodsworth et al. 1991; Cheruvu et al. 2007; Filippini et al. 2007). However, there are considerable geographic differences in this rate, as for example in immigrants and refugees (Rossi et al. 2012). Additionally, co-infected patients often present with an elevated, sustained serum HBV DNA level, with less likelihood of spontaneous HBsAg and HBeAg seroconversion—the loss of HBsAg with development of an anti-HBsAg antibody and the loss of HBeAg with development of an anti-HBeAg antibody, respectively (Biggar et al. 1987; Bodsworth et al. 1989, 1991; Gilson et al. 1997; Lazizi et al. 1988). On the other hand, HBV and/or HCV infection can drive HIV infection with more rapid progression to AIDS, perhaps explained by an increased viral load in HIV-infected cells and a faster decline as well as lower nadir of CD4+ cell counts (Eskild et al. 1992; Horvath and Raffanti 1994). Additionally, activation factors such as Nef, Tat, Rantes, Mip-1 for HIV, and X-protein, nuclear factor (NF)-1, NF-3, AP-1 for HBV, are activated intracellularly as well as extracellularly and lead to enduring activation of cells. Co-infection of HBV in HCV patients leads to more severe liver disease as well, with higher rates and faster progression to liver cirrhosis and liver cancer (Bodsworth et al. 1991; Filippini et al. 2007).
HBV Vaccine Response is Blunted in HCV and/or HIV-Infected Individuals
HBV vaccine is the primary means to prevent HBV infection and liver-related diseases. Because co-infection increases liver-related mortality, it is highly recommended that HIV- and/or HCV-infected individuals who lack evidence of previous infection or immunity be immunized for HBV, with either Engerix® HBV, Fendrix® or HBVaxPro-40®, or Twinrix® HAV/HBV combination vaccine if the individual is non-immune to hepatitis A virus (HAV). Notably, the combination of HAV and HBsAg in Twinrix® induces a higher immune response against HBsAg, and a combined vaccine from a further manufacturer is not commercially available. However, compared with the general population, the response rates to HBV vaccine (defined as development of anti-HBsAg with titer >10 IU/L) in HIV and/or HCV-infected patients is significantly diminished (20–70 vs. 90–95 %) (Collier et al. 1988; Kao and Chen 2002; Keeffe 2005; Kramer et al. 2009; Shafran et al. 2007; Tsai et al. 2000). Recent studies suggest that the anti-HBsAg protective level of 10 IU/L is no longer sufficient and has been proposed to be elevated to around 100 IU/L (Allain and Canotti 2012; Stramer et al. 2011).
The efficacy of HBV vaccination varies depending on the immune status of the recipients. For example, HBV hypo-responsiveness is strongly correlated with aging, with seroconversion rates showing declines as early as age 35 and markedly waning over the ensuing decades (Fisman et al. 2002). Following a full vaccination series, 90 % of healthy adults and 95 % of infants and children have protective serum antibody concentrations (Kao and Chen 2002; Tsai et al. 2000). Antibody levels usually decline with time to below the protective level of 10 IU/L in up to 50 % of vaccinees after 15 years; but clinically significant breakthrough infections are rare. There is also a marked sex difference in response to HBV vaccine (Klein 2012; Klein et al. 2010).
In patients with HIV infection, the poor response rate is closely related to CD4+ cell counts. However, recent data show that even in the setting of CD4 counts >200 or 500 cells/mm3, seroconversion rates in HIV-infected patients are still much lower than age-matched healthy subjects (Shafran et al. 2007). In the case of HCV infection, vaccine response is related to the stage of liver disease at the time of vaccine initiation, with poor response in those with severe liver fibrosis and cirrhosis (Kramer et al. 2009). Nevertheless, our recent data suggest that even in the setting of relatively preserved hepatic function, seroconversion rates in HCV-infected individuals are still much lower than age-matched healthy subjects (53 vs. 94 %) (Moorman et al. 2011). Interestingly, HCV patients who receive Twinrix vaccination have a better response rate than those who receive HBV vaccine alone, suggesting that HAV antigen in the Twinrix might enhance the HBV vaccine response.
The phenomenon of poor response to immunizations in HIV/HCV-infected patients has also been found with other vaccines in addition to HBV, including HAV, influenza, or pneumococcal vaccines (Malaspina et al. 2005; Rodriguez-Barradas et al. 2003). Additionally, similar phenomena are also observed following routine adult immunizations in the setting of other immunosuppressive conditions, such as organ transplantation, cancer chemotherapy, and chronic renal failure, suggesting a universal or shared mechanism of vaccine nonresponse in immunocompromised hosts.
To improve the seroconversion of HBV immunization, several approaches—including different administration routes (subcutaneous vs. intradermal injection), higher doses of HBV vaccine (40 vs. 20 μg), and adding adjuvants (CPG 7909, levamisole, GM-CSF)—have been tried for nonresponders (Jacques et al. 2002; Kim et al. 2003; Nystrom et al. 2008; Rahman et al. 2000; Ramon et al. 1996). These approaches have led to varying degrees of improvement in healthy subjects, but have had limited success in virally infected individuals, in part due to a lack of information regarding cellular and molecular mechanisms that inhibit immune responses in this setting.
Possible Mechanisms Involved in HBV Vaccine Failure During Chronic Viral Infections
The reasons for vaccine nonresponse in 5–10 % of healthy subjects and 40–60 % of HCV or HIV-infected individuals remain poorly understood, although several factors are known to play a role, such as age, gender, smoking, obesity, and certain human leukocyte antigen (HLA) alleles (De Silvestri et al. 2001; Godkin et al. 2005; Lango-Warensjo et al. 1998). More specifically, nonresponsiveness to HBV vaccine in adults is strongly associated with the HLA-C4A locus. This association was also demonstrated in neonates who failed to mount a successful antibody response to challenge with HBV vaccine (De Silvestri et al. 2001). Additionally, HLA-DRB1*0301 has been associated with nonresponse to vaccination with HBV envelope proteins (HBsAg), with no altered susceptibility to viral persistence (Godkin et al. 2005). Interestingly, the amino acids that differ between the responders and the nonresponders are located in the peptide-binding groove of the HLA molecule, which seems to determine the response against HBsAg (Lango-Warensjo et al. 1998). These results suggest a role for HLA alleles to direct either a response or a nonresponse against HBsAg. Notably, some HLA class II genotypes were found to be identically shared by vaccine responders and nonresponders, indicating the influence of other factors in addition to the HLA system in the response to HBV vaccine. Additional causes besides HLA that may influence the HBV immune response include host genetic factors and cytokine genetic polymorphisms, amongst others (Macedo et al. 2010; Ryckman et al. 2010).
The mechanism for vaccine-induced immune responses is thought to be clonal activation and expansion of antigen-specific memory T and B lymphocytes upon encountering antigen. Given the fact that these nonresponders also have poor recall responses to tetanus toxoid or Candida, it has been suggested that HBV vaccine failure may be due to a defect in HBsAg-reactive T cells (Albarran et al. 2005; Bauer and Jilg 2006; Goncalves et al. 2004; Salazar et al. 1995), or in antigen-presenting cells (APCs) (Hohler et al. 2002; Verkade et al. 2007). Indeed, a recent study of patients with chronic renal disease who failed HBV vaccination revealed a more profound defect in monocyte-derived dendritic cell function, leading to diminished helper T cell and B cell responses (Verkade et al. 2007). Thus, it appears that defective APC and impaired helper T cell functions may underlie the dampened B cell response to vaccination, although this remains controversial (Desombere et al. 1995, 2005). Another study of HBV vaccine response in liver transplant recipients shows evidence of accumulation of HBsAg-specific regulatory T cells (Bauer et al. 2007), suggesting that broader immune modulations may play a pivotal role in vaccine response during chronic viral infections.
Immune Exhaustion in HBV Vaccine Failure During Chronic Viral Infections
It is well established that the immune system is precisely regulated by an intricate balance between positive and negative signals to ensure adequate responses against pathogens and yet prevent over-activation of lymphocytes and thus cause autoimmunity. The activation and proliferation of lymphocytes requires two signals: an antigen-specific signal (signal 1) and a co-stimulatory signal (signal 2) that is independent of the antigen receptor complex. While signal 1 determines the antigen-specific reaction, co-stimulatory signal 2 is pivotal in determining whether recognition of antigen by T-helper lymphocytes leads to full cell activation and proliferation or to cell exhaustion and apoptosis.
Besides positive stimulatory signaling, the immune system has developed negative feedback mechanisms to prevent unnecessary activation of immune responses. The recently described programmed death-1 (PD-1), suppressor of cytokine signaling-1 (SOCS-1) and T cell immunoglobulin domain protein-3 (Tim-3) inhibitory pathways represent such feedback mechanisms to maintain the balance between positive and the negative intracellular signals in T and B lymphocytes following antigenic encounter (Alexander 2002; Chen 2004; Egan et al. 2003; Hafler and Kuchroo 2008; Kuchroo et al. 2003; Nishimura and Honjo 2001; Okazaki and Honjo 2007; Sharpe and Freeman 2002). Compelling evidence is emerging for the involvement of these negative signaling molecules in antiviral immune evasion, autoimmune responses, and tumorigenesis (Barber et al. 2006; Boni et al. 2007; Chong et al. 2005; Dong et al. 2002; D’Souza et al. 2007; Golden-Mason et al. 2007; Iwai et al. 2003; Jin et al. 2010; Jones et al. 2008; Khoury and Sayegh 2004; McMahan et al. 2010; Morita et al. 2000; Vali et al. 2010), which raises the possibility that therapeutic strategies targeting these inhibitory pathways might be of clinical benefit.
Immune Senescence in HBV Vaccine Failure During Chronic Viral Infections
Accumulating evidence suggests that cells of the immune system may have a limited lifespan in vivo following repeated antigenic stimulation. In this context, persistent activation during chronic HIV and/or HCV infection may lead to an exhaustion as well as senescence of immune resources. This may occur at two levels: clonal (virus-specific suppression) and global (general immune suppression). Some virus-specific T lymphocytes start expressing senescence markers (CD57, p16ink4a, KLRG-1, loss of CD28) soon after primary infection. Persistently activated, virus-specific T cell clones may eventually reach stages of senescence and disappear through cell apoptosis, resulting in the loss of antigen-specific CD4+ and/or CD8+ T cell populations important to controlling viral replication. In addition, HIV infection is characterized by the accumulation of highly differentiated CD8+CD28− T cells over time. Along with the decline of T cell renewal capacities, this may reflect a general aging of the lymphocyte population. Similar observations have been found in non-infected elderly individuals, suggesting that premature immune senescence occurs in the setting of chronic viral infections as a result of persistent immune stimulation. Accelerated immunosenescence in the setting of HIV/HCV diseases results in an aging state that diminishes the ability of the immune system to contain virus while at the same time facilitating viral replication and spread. Clinically, these changes result in a lower capacity to respond to new infections or vaccines as well as an increased frequency of age-associated end-organ disease (e.g. cardiovascular complications, cancer, and neurologic disease) that is associated with increased morbidity and mortality.
Essential features of immune senescence include reduced number and function of APCs in blood; reduced natural killer cell cytotoxicity; and decreased naive T and B cells with an increase in terminally differentiated lymphocytes. In particular, an accumulation of late differentiated effector/memory T cells contributes to a decline in the capacity of the adaptive immune system to respond to novel antigens. Consequently, vaccine responsiveness is compromised in the elderly, especially frail patients, as well as virally infected individuals. Indeed, we have recently found a significantly increased CD8+CD28− T cell accumulation in HCV-infected, HBV vaccine nonresponders versus responders (unpublished data). In the future, the development and use of markers of immunosenescence to identify patients who may have impaired responses to vaccination, as well as the use of end-points other than antibody titers to assess vaccine efficacy, may help to reduce morbidity and mortality due to chronic viral infections.
Because of the effect of aging on APC function, Treg-mediated immune suppression, reduced proliferative capacity of T cells, and other diminished immune responses, the efficacy of vaccines often wanes with advanced age. Strikingly, chronic HIV/HCV infections compress the aging process, accelerating comorbidities and frailty. A recent study demonstrated that young HIV-infected patients with less than 4 years of infection have early immune exhaustion leading to premature aging and senescence that is comparable to the elderly, suggesting virus-induced premature immune senescence associated with high rates of immune exhaustion following short-term infection (Ferrando-Martínez et al. 2011). We have also explored the role of HCV-mediated immune exhaustion and immune senescence in HBV vaccine responses during chronic HCV infection. We found that HCV-infected individuals exhibit higher expressions of both exhaustion and senescence markers—including PD-1/Tim-3 and KLRG-1/p16ink4a—in APC or helper T cells; this is associated with impaired cellular functions that are more significant in HBV vaccine non-responders compared with responders (unpublished data). Additionally, we have previously demonstrated that HCV arrests cell cycle progression through stabilization of p27kip1—an inhibitor of cell cycle regulatory proteins CDK and cyclin D/E (Yao et al. 2003). These findings have led to an intersection of the fields of virus-mediated immune exhaustion and immune senescence with regard to vaccine responses (Fig. 3). The mechanisms behind how HIV/HCV infection induces immune exhaustion and immune senescence, and whether these two distinct pathways interact each other during immune responses, have yet to be clearly defined but are essential for developing specific strategies to improve vaccine responses in the setting of viral infection.
Immune exhaustion and immune senescence are two distinct signaling pathways that coordinately regulate cell function and fate. Further investigation into their roles in vaccine responses during chronic viral infections is critical to identifying high priority topics and gaps for future research. Although there has been substantial progress in identifying the mechanisms that regulate both processes separately, it is unclear how these processes interrelate and whether blocking pathways that maintain either the exhausted or the senescent state or both can boost vaccine responses, especially in chronically virus-infected individuals. Answers to the questions posed are likely to help prioritize and balance strategies to slow the progression of persistent viral infections, to address co-morbidities and drug toxicity, and to enhance our understanding of the underlying mechanisms for HIV/HCV infections and their associated poor vaccine responses. Investigation in this area has the potential to improve vaccine development and advise more effective strategies to reduce the risk of vaccine-preventable illness in chronically virus-infected individuals. Additionally, novel approaches, such as viral vectors for antigen delivery, DNA-based vaccines and innovative adjuvants, and in particular Toll-like receptor agonists, may help to achieve optimal vaccine protection against chronic infectious diseases. Such studies will lead to novel guidelines for improving the vaccine response in immunocompromised hosts who are at high risk for infection, ultimately initiating steps to reduce clinical morbidity and mortality.
This work was supported by an NIH NIDDK grant to ZQY/JPM (R01DK093526). The authors disclose no conflicts of interest. They would like to appreciate the supporting staff from the Hepatitis (HCV/HIV) Program at James H. Quillen VAMC. This publication is the result of work supported with resources and the use of facilities at the James H. Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.